Does glucosamine use increase the risk of cardiovascular disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Glucosamine and Cardiovascular Disease Risk: Conflicting Evidence

The relationship between glucosamine and cardiovascular disease is highly controversial, with recent evidence showing both protective and harmful associations depending on the population studied and adherence patterns—I recommend against routine glucosamine use for osteoarthritis given the strong guideline recommendation against its efficacy, and advise caution regarding cardiovascular effects, particularly in patients who would use it adherently long-term.

Guideline Position on Glucosamine

The 2019 ACR/Arthritis Foundation guideline strongly recommends against glucosamine use in knee, hip, and hand osteoarthritis 1. This represents a strengthening from prior conditional recommendations, based on:

  • Industry-sponsored studies showing efficacy while publicly-funded studies do not
  • High risk of publication bias
  • Lack of important benefits over placebo when examining low-bias studies
  • Large placebo effects

The guideline notes glucosamine has low toxicity, though some patients may experience elevated serum glucose 1. Notably, the guideline does not mention cardiovascular risks, as this was not part of their systematic review scope.

The Cardiovascular Evidence Paradox

Evidence Suggesting Harm

The most recent large-scale study from China (2022,685,778 subjects) found glucosamine use significantly increased cardiovascular disease risk 2:

  • Overall CVD: HR 1.10 (95% CI: 1.08-1.11)
  • Coronary heart disease: HR 1.12 (95% CI: 1.09-1.15)
  • Adherent users showed highest risk: HR 1.68 (95% CI: 1.59-1.78)
  • Clear dose-response relationship (p-trend < 0.001)

A 2025 mechanistic study demonstrated that long-term high-dose glucosamine increased atrial fibrillation susceptibility in mice by impairing AMPK signaling, causing electrical and structural atrial remodeling 3.

Evidence Suggesting Protection

Conversely, UK Biobank studies show protective associations:

  • 2019 study (466,039 participants): HR 0.85 for total CVD events (95% CI: 0.80-0.90) 4
  • 2026 diabetes/prediabetes subgroup (54,096 participants): HR 0.94 for overall CVD (95% CI: 0.91-0.96), with stronger effects in those with low CRP levels 5
  • 2025 study showed reduced cardiovascular disease in metabolic liver disease patients 6

Reconciling the Contradiction

The divergent findings likely reflect:

  1. Population differences: Chinese healthcare claims data 2 versus UK Biobank volunteers 5, 4—the latter represents a healthier, more health-conscious cohort (healthy-user bias)

  2. Adherence patterns: The Chinese study uniquely stratified by adherence, showing harm only in adherent users (HR 1.68), while non-adherent users showed minimal risk (HR 1.03) 2. UK studies did not assess adherence.

  3. Confounding: All studies are observational. The UK studies' protective findings may reflect unmeasured healthy behaviors in supplement users rather than true glucosamine effects 7.

Clinical Recommendation Algorithm

For patients considering glucosamine:

  • Do not recommend glucosamine for osteoarthritis treatment based on strong guideline evidence of inefficacy 1

  • If patients insist on using glucosamine despite counseling:

    • Warn about potential cardiovascular risk with adherent, long-term use 2
    • Monitor for atrial fibrillation symptoms (palpitations, irregular pulse) 3
    • Consider baseline and periodic glucose monitoring 1
    • Emphasize that perceived benefits are likely placebo effects 1

  • Higher cardiovascular concern in:

    • Patients planning adherent, daily long-term use
    • Those with existing cardiovascular risk factors
    • Asian populations (where the harm signal was detected)

  • Counsel that effective OA treatments exist (weight loss, exercise, NSAIDs, intraarticular injections) that don't carry these uncertainties

Critical Caveats

The protective UK Biobank findings 5, 4 are likely confounded by healthy-user bias—people who take supplements tend to have healthier lifestyles overall. The Chinese study's 2 finding of harm specifically in adherent users, with a clear dose-response relationship, is more biologically plausible and concerning. The mechanistic data showing AMPK impairment and atrial fibrillation 3 provides a potential pathway for harm.

Given glucosamine lacks efficacy for its intended use 1 and carries uncertain but potentially harmful cardiovascular effects 2, 3, there is no clinical justification for its use.

References

Related Questions

What is the recommended management for a dermoid cyst on the face?
What is the appropriate evaluation and management for a 63-year-old man with progressive loss of sensation in his index finger?
What are the contraindications for glucosamine‑chondroitin supplementation?
What is the next step in diagnosis and initial treatment for a patient with right pleuritic chest pain, decreased breath sounds on the right, leukocytosis (white blood cell count 32 × 10⁹/L), and a chest radiograph showing clear lung fields but an elevated right hemidiaphragm?
What alternative management should be considered for a dental infection that is not responding to amoxicillin‑clavulanate?
What dangerous symptoms should I watch for while taking Eliquis (apixaban)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.